AHA and LifePod start remote monitoring trial for heart disease patients
September 3, 2019
The American Heart Association (AHA) is working with Massachusetts-based LifePod on a remote patient monitoring trial among those suffering from chronic heart conditions.
LifePod provides a proactive-voice caregiving service. It has joined AHA’s Center for Health Technology & Innovation’s innovators network. The centre is focused on building and fostering health technology relationships to drive innovative and scalable services across the health continuum and helping members of the innovators network integrate their technology with the AHA’s digital resources to encourage development of digital healthcare.
The study aims to explore the impact of LifePod’s proactive, personaliseable service in helping patients with heart failure adhere to the centre’s science-based health management plans, called CarePlans.
Medication non-adherence contributes to upwards of $300bn a year in avoidable healthcare spending. LifePod’s service can help reduce this cost and improve the patient experience by proactively monitoring and supporting patients with two-way, voice-first medication reminders and diet and exercise encouragement in between doctor’s visits.
Unlike reactive voice assistants that can only respond to patients when spoken to, LifePod has the ability to speak to the patient without being prompted. As important, the proactive dialogues can be configured on LifePod’s cloud-based caregiver portal, enabling personalisation in accordance with each patient’s needs.
“We’re excited to collaborate with LifePod on this study and we look forward to applying our unique cardiovascular research expertise to help improve health education and health engagement,” said Patrick Wayte, AHA senior vice president.
Professional caregivers and family members can remotely monitor and support their patients or loved ones throughout the day, every day, without relying on intrusive video links or being there in person.
“We are proud to collaborate with the association with the goal of enabling patients with heart conditions to live longer, healthier lives,” said Stuart Patterson, co-founder and CEO of LifePod. “Our tests have shown that the personalised nature and intuitive UI of LifePod’s proactive-voice service can empower caregivers to address the gaps in behavioural and social support that contribute to medication and behavioural non-adherence, potentially extending patients’ lives and saving providers billions in avoidable costs.”
The news comes on the heels of LifePod’s pilot programme with the Commonwealth Care Alliance (CCA), which resulted in the CCA deciding to expand LifePod’s caregiving service to approximately 500 additional CCA members.
The AHA and LifePod will form a governing board of healthcare experts, including representatives from the association, LifePod and the CCA to design the initial programme study with a cohort of 50 to 100 patients at risk of heart failure.
LifePod is at proactive-voice, AI-powered caregiving service developed to support and improve the quality of care and life for both caregivers and care recipients throughout their journey.